Global Active B12 Test Market Size By Type (ELISA assay, Enzyme immunoassay), By Application (Folate deficiency anemia, Pernicious anemia), By Region, And Segment Forecasts, 2023 to 2032

The Global Active B12 Test Market was valued at USD 240 million in 2023 and is projected to reach USD 438 million by 2031, expanding at a CAGR of 7.9% during the forecast period from 2023 to 2031. This growth is driven by the rising prevalence of vitamin B12 deficiency, increasing geriatric population, and growing awareness regarding early diagnosis of nutritional deficiencies. Active B12 (holotranscobalamin) testing is considered a more accurate method than total B12 measurement, making it crucial in diagnosing functional deficiencies and neurological disorders at an early stage.

Drivers

1. Rising Prevalence of Vitamin B12 Deficiency

Increased incidence of vitamin B12 deficiency globally, especially among the elderly, vegetarians, and individuals with gastrointestinal disorders, is boosting the demand for active B12 tests for accurate diagnosis and monitoring.

2. Increased Awareness and Screening Programs

Healthcare organizations are promoting vitamin and micronutrient deficiency awareness, encouraging preventive screening. This trend is particularly evident in developed countries with aging populations and proactive wellness approaches.

3. Advancements in Diagnostic Technology

Improved immunoassay techniques and the automation of diagnostic processes are enhancing the accuracy, sensitivity, and efficiency of active B12 testing, propelling market growth.

Restraints

1. High Cost of Testing

The relatively higher cost of active B12 tests compared to conventional total B12 tests remains a barrier, particularly in price-sensitive and low-income regions.

2. Limited Awareness in Developing Regions

Despite rising health concerns, there is still a lack of awareness about the benefits of active B12 testing among both healthcare providers and patients in several developing economies.

Opportunity

1. Expansion into Emerging Markets

Emerging countries such as India, Brazil, and parts of Southeast Asia present significant growth opportunities due to increasing healthcare expenditure and improving diagnostic infrastructure.

2. Integration with Preventive Health Packages

The inclusion of active B12 testing in preventive healthcare and wellness programs is gaining momentum, especially among corporate and private health initiatives, enhancing test uptake.

Market by System Type Insights

By system type, the Immunoassay Analyzer segment dominated the global active B12 test market in 2023. Immunoassay-based systems offer high sensitivity and specificity, making them ideal for active B12 detection. The growing adoption of automated platforms in clinical labs and hospitals supports the segment's dominance and continued growth.

Market by End-use Insights

Among end-users, the Hospital and Diagnostic Laboratories segment held the largest market share in 2023, accounting for over 60% of the revenue. Hospitals and diagnostic labs are the primary settings for vitamin B12 testing, driven by high patient footfall, access to advanced instruments, and insurance-covered testing services.

Market by Regional Insights

North America led the global active B12 test market in 2023, supported by high healthcare awareness, advanced diagnostic infrastructure, and favorable reimbursement policies. Meanwhile, Asia-Pacific is expected to witness the fastest growth through 2031, driven by increasing healthcare spending, growing awareness, and government-led health screening initiatives.

Competitive Scenario

Key players in the global active B12 test market include Axis-Shield Diagnostics Ltd., Abbott Laboratories, Siemens Healthineers, Roche Diagnostics, Beckman Coulter Inc., DiaSorin S.p.A., Thermo Fisher Scientific, and PerkinElmer Inc. These companies are investing in R&D, automation, and strategic collaborations to expand their diagnostic product lines and enhance market reach.

Scope of Work – Global Active B12 Test Market

Report Metric Details

Market Size (2023) USD 240 million

Projected Market Size (2031) USD 438 million

CAGR (2023–2031) 7.9%

Market Segments By System Type, By End-use, By Region

Growth Drivers Rising B12 deficiency, Advancements in diagnostics, Screening awareness

Opportunities Emerging markets, Preventive health integration

Key Market Developments

2023: Abbott Laboratories expanded its diagnostic test offerings in Asia-Pacific, including active B12 assays, aiming to strengthen its presence in emerging markets.

2023: Siemens Healthineers launched a high-throughput immunoassay platform integrated with advanced B12 deficiency markers for early detection.

2024: Roche Diagnostics announced partnerships with regional health networks in Europe to integrate active B12 testing into regular wellness checkups.

FAQs

1) What is the current market size of the Global Active B12 Test Market?

The Global Active B12 Test Market was valued at USD 240 million in 2023.

2) What is the major growth driver of the Global Active B12 Test Market?

The major growth driver is the rising prevalence of vitamin B12 deficiency and the growing demand for accurate early diagnostic tools.

3) Which is the largest region during the forecast period in the Global Active B12 Test Market?

North America holds the largest market share, while Asia-Pacific is projected to grow the fastest.

4) Which segment accounted for the largest market share in Global Active B12 Test Market?

The Hospital and Diagnostic Laboratories segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Active B12 Test Market?

Key players include Abbott Laboratories, Siemens Healthineers, Roche Diagnostics, Axis-Shield Diagnostics Ltd., and Beckman Coulter Inc.